Relationship Between Disease Severity and Inflammatory Markers in Cystic Fibrosis
Overview
Authors
Affiliations
To evaluate the clinical use of measuring neutrophil, lymphocyte, and eosinophil activities, serum myeloperoxidase (MPO), soluble interleukin-2 receptors (sIL-2R), and eosinophil cationic protein (ECP) were measured in 98 patients with cystic fibrosis and in 85 healthy children. Serum concentrations of MPO, sIL-2R, and ECP were increased in patients with cystic fibrosis (median 807 micrograms/l, 4452 pg/ml, 48.8 micrograms/l, respectively) compared with the controls (median 319 micrograms/l, 2743 pg/ml, 9.4 micrograms/l). ECP concentrations, but not serum MPO or sIL-2R, were significantly related to disease severity assessed by the Shwachman-Kulczycki score and by pulmonary function (forced expiratory volume in one second % predicted). Neither ECP nor sIL-2R was influenced by Pseudomonas aeruginosa infection, acute pulmonary exacerbation, or atopy. Serum MPO, however, was strongly correlated with acute pulmonary exacerbation. In the light of these findings the measurement of serum ECP might thus be used for clinical monitoring and for assessing disease severity in cystic fibrosis. The measurement of serum MPO and sIL-2R did not correlate with the disease severity.
Causer A, Shute J, Cummings M, Shepherd A, Gruet M, Costello J Redox Biol. 2020; 32:101436.
PMID: 32044291 PMC: 7264436. DOI: 10.1016/j.redox.2020.101436.
Environmental allergies and respiratory morbidities in cystic fibrosis.
Collaco J, Morrow C, Green D, Cutting G, Mogayzel Jr P Pediatr Pulmonol. 2012; 48(9):857-64.
PMID: 23143815 PMC: 3572264. DOI: 10.1002/ppul.22700.
Potential of anti-inflammatory treatment for cystic fibrosis lung disease.
Taylor-Cousar J, Von Kessel K, Young R, Nichols D J Inflamm Res. 2011; 3:61-74.
PMID: 22096358 PMC: 3218732. DOI: 10.2147/jir.s8875.
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.
Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P Respir Res. 2006; 7:134.
PMID: 17064416 PMC: 1637104. DOI: 10.1186/1465-9921-7-134.
Schmitt-Grohe S, Zielen S Paediatr Drugs. 2005; 7(6):353-63.
PMID: 16356023 DOI: 10.2165/00148581-200507060-00004.